[
    [
        {
            "time": "",
            "original_text": "医药生物行业研究周报：建议以中期维度看医药行情",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "行业研究",
                    "中期维度",
                    "行情"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业研究周报：建议以中期维度看医药行情",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "520国际临床试验日：为希望而试，用科学告白",
            "features": {
                "keywords": [
                    "国际临床试验日",
                    "科学",
                    "希望"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科研"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "520国际临床试验日：为希望而试，用科学告白",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "泡沫？国内CXO巨头营收仅为昆泰的1/4，市值却位列全球第一，凭什么？",
            "features": {
                "keywords": [
                    "泡沫",
                    "CXO",
                    "营收",
                    "市值",
                    "昆泰",
                    "全球第一"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泡沫？国内CXO巨头营收仅为昆泰的1/4，市值却位列全球第一，凭什么？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]